INFORMACIÓN BÁSICA SOBRE COOKIES

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web.
La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias.
Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso.
En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web.
Más información en el apartado POLÍTICA DE COOKIES de nuestra página web.

ACEPTAR RECHAZAR

LIST OF CLINICAL TRIALS

Search for clinical trials open in our centers by cancer type.

PLEASE MAKE A SELECTION TO
BROWSE RESULTS

OPEN TRIAL CLOSED TRIAL

LUNG AND PLEURAL CANCER

LUNAR [OPEN TRIAL]

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in combination with PD-1 inhibitors or docetaxel, for second line treatment of non-small cell lung cancer (NSCLC).

+ INFO

LUNG AND PLEURAL CANCER

M14-361 [OPEN TRIAL]

A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer.

+ INFO

LUNG AND PLEURAL CANCER

MESOS [OPEN TRIAL]

A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma.

+ INFO

LUNG AND PLEURAL CANCER

NADIM [OPEN TRIAL]

Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non small cell lung cancer (NSCLC): a phase II multicenter exploratory study

+ INFO

LUNG AND PLEURAL CANCER

NIVEX [OPEN TRIAL]

A retrospective, multicenter and observational study of Nivolumab monotherapytreatment in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received atLeast One Prior Systemic Regimens for the Treatment of Stage IIIb/IV NSCLC withinthe Expanded Access Program (EAP) in Spain. Protocol: GECP 16/05

+ INFO

LUNG AND PLEURAL CANCER

NVALT-15 [OPEN TRIAL]

Phase II study with BIBF1120, an oral inhibitor of fibroblast growth factor 1 as second-line treatment in patients with small cell lung cancer and amplification of the fibroblast growth factor receptor 1 gene.

+ INFO

BREAST CANCER

OLYMPIA [OPEN TRIAL]

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

+ INFO

BREAST CANCER

PALLAS [OPEN TRIAL]

Phase III randomized study of palbociclib with standard adjuvant endocrine treatment versus standard adjuvant endocrine monotherapy for primary breast cancer positive for hormone receptor (HR +) and HER2-negative. Protocol: AFT–05 ABCSG 42 BIG 14‐03

+ INFO

BREAST CANCER

PATINA [OPEN TRIAL]

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of PAlbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 therapy + Endocrine therapy after Induction treatment for Hormone Receptor Positive (HR+) / HER2-Positive Metastatic BreAst Cancer. Protocol: AFT –38

+ INFO

LUNG AND PLEURAL CANCER

PIPSEN [OPEN TRIAL]

A Randomized double-bind phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer.

+ INFO